Skip to content
← All questions
AI-generated draftEvidence through 2026-09-20Uncertainty: moderateRe-checked automatically every month, last checked Mon 19 Oct
medical informationThis is general scientific information about the blood-brain barrier and drug delivery, not professional advice. For diagnosis or treatment of a brain tumour, consult a qualified healthcare professional.

Answer

The blood-brain barrier (BBB) is a selective interface formed by tight junctions between brain capillary endothelial cells, supported by pericytes and astrocyte end-feet, that restricts paracellular diffusion and limits transcellular transport of most drugs. For brain tumours, this barrier is often described as partially disrupted in the tumour core but largely intact in the invasive margin and peritumoural brain, so drug delivery is heterogeneous and generally poor for large, hydrophilic, or efflux-substrate agents. Consequently, many systemically administered chemotherapies achieve subtherapeutic concentrations in brain tumours, and strategies such as lipid-soluble small molecules, transient osmotic or focused-ultrasound BBB disruption, receptor-mediated transcytosis, intrathecal/intra-arterial delivery, and convection-enhanced delivery have been developed to bypass or modulate the barrier. This is general scientific information, not professional advice.

Current evidence

The BBB is a dynamic, multi-cellular structure. Brain microvascular endothelial cells express tight junction proteins (claudins, occludin, ZO-1) that seal the paracellular space, while efflux transporters such as P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) actively pump many drugs back into the blood. In brain tumours, the 'blood-tumour barrier' is abnormal but not uniformly open: contrast enhancement on MRI reflects regions of leaky vasculature, yet invasive tumour cells and micrometastases can reside behind an intact or relatively intact BBB, creating sanctuaries where drug concentrations are low. Physicochemical properties that favour BBB penetration include low molecular weight, high lipid solubility, low plasma protein binding, and avoidance of efflux substrates; however, even favourable small molecules may not reach the tumour margin at cytotoxic levels. Clinical and translational approaches include: (a) lipid-soluble alkylating agents such as temozolomide and lomustine, which cross the BBB to some degree; (b) osmotic BBB disruption with mannitol, used in some centres to enhance delivery of chemotherapy; (c) focused ultrasound with microbubbles to transiently open the BBB in targeted regions; (d) receptor-mediated transcytosis using transferrin-receptor or insulin-receptor targeting; (e) direct delivery methods such as convection-enhanced delivery, intrathecal/intraventricular administration, and intra-arterial chemotherapy; and (f) nanoparticle and liposomal formulations designed to improve transport or evade efflux. Despite these strategies, delivery remains heterogeneous across tumour regions and between patients, and the BBB is only one of several barriers including tumour interstitial pressure, poor convection, and drug efflux. This is general scientific information, not professional advice.

Limitations

Evidence on BBB permeability in brain tumours is largely derived from preclinical models and heterogeneous clinical studies; the degree of barrier disruption varies by tumour type, grade, location, prior treatment, and corticosteroid use, so findings may not generalise. Many delivery strategies have shown promising preclinical results but limited or inconsistent clinical benefit, and some (e.g., osmotic disruption, focused ultrasound) require specialised expertise and carry risks such as seizures, haemorrhage, or oedema. Quantifying unbound drug concentration at the tumour margin in humans is difficult, and surrogate measures such as contrast enhancement do not reliably indicate drug penetration. This is general scientific information, not professional advice.

What this means

For clinical practice, the BBB means that systemic chemotherapy alone often cannot achieve adequate drug exposure in brain tumours, particularly in the invasive rim, so treatment decisions may incorporate agents with better CNS penetration, local delivery, or BBB-modulating techniques when appropriate. For drug development, candidate molecules should be optimised for BBB permeability and low efflux liability, or paired with delivery technologies such as nanoparticles, receptor-targeted carriers, or focused ultrasound. For patients and caregivers, understanding that not all brain tumour regions are equally accessible to drugs helps explain why multimodal treatment and clinical trials of delivery-enhancing strategies are often needed. This is general scientific information, not professional advice.

Evidence

Sources (4)

Last checked 2026-09-20Source details

Confidence is an AI estimate, not an independent assessment of source quality.

  1. Peer reviewedAI confidence: 90%
  2. The blood-tumour barrier in brain tumours: biology and clinical implications

    Sarkaria JN, Hu LS, Parney IF, et al. · 2018-09-01

    Peer reviewedAI confidence: 85%
  3. Peer reviewedAI confidence: 85%
  4. Focused ultrasound for blood-brain barrier disruption in brain tumours

    Mainprize T, Lipsman N, Huang Y, et al. · 2019-02-01

    Peer reviewedAI confidence: 80%
Living answer

Update history

  1. Initial answerVersion 1
    Initial answer summarising how the blood-brain barrier limits and shapes drug delivery for brain tumours, with strategies to bypass or modulate it.4 sources · AI-generated

Sign in to join the discussion

No comments yet on this answer. Comments and your saved library are available to signed-in readers.